

Unless otherwise defined in this announcement, terms defined in the prospectus of Jacobson Pharma Corporation Limited (the “**Company**”) dated 8 September 2016 (the “**Prospectus**”) have the same meanings when used in this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not an offer of securities for sale in the United States. The securities described herein have not, and will not, be registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or with any securities regulatory authority of any state or other jurisdiction in the United States and may not be offered or sold, directly or indirectly, in the United States unless the securities are so registered or an exemption from the registration requirements is available. The Hong Kong Offer Shares are being offered and sold outside the United States in offshore transactions in accordance with Regulation S under the U.S. Securities Act. There will not and is not currently intended to be any public offering of securities in the United States. Any public offering of securities in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and its management, as well as its financial statements.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Jacobson Pharma Corporation Limited**  
**雅各臣科研製藥有限公司**

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

**FULL EXERCISE OF  
THE OVER-ALLOTMENT OPTION**

The Company announces that the Over-allotment Option described in the Prospectus was fully exercised by the Sole Global Coordinator (on behalf of the International Underwriters) on 3 October 2016 (after trading hours) in respect of 65,625,000 additional new Shares (the “**Over-allotment Shares**”), representing 15% of the Offer Shares initially available under the Global Offering before the exercise of the Over-allotment Option. The Over-allotment Shares will be issued and allotted by the Company at HK\$1.50 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering. A further announcement will be made by the Company after the end of the stabilisation period.

## FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus was fully exercised by the Sole Global Coordinator (on behalf of the International Underwriters) on 3 October 2016 (after trading hours) in respect of 65,625,000 additional new Shares, representing 15% of the Offer Shares initially available under the Global Offering before the exercise of the Over-allotment Option.

The Over-allotment Shares will be issued and allotted by the Company at HK\$1.50 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering.

Approval for the listing and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of and dealings in such Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on 6 October 2016.

### Shareholding structure upon the issue and allotment of the Over-allotment Shares

The shareholding structure of the Company immediately before and immediately after the completion of the issue and allotment of the Over-allotment Shares by the Company is as follows:

| Shareholders  | Immediately before<br>the issue and allotment of<br>the Over-allotment Shares |   | Immediately after<br>the issue and allotment of<br>the Over-allotment Shares |   |
|---|---|---|--|---|
|   | Number of<br>Shares   | Approximate<br>percentage of<br>the Company's<br>issued share<br>capital (%) <sup>(1)</sup> | Number of<br>Shares  | Approximate<br>percentage of<br>the Company's<br>issued share<br>capital (%) <sup>(1)</sup> |
| Kingshill <sup>(2)</sup>                            | 850,684,000   | 48.61%  | 850,684,000  | 46.85%  |
| Longjin <sup>(2)</sup>                              | 157,050,000   | 8.97%   | 157,050,000  | 8.65%   |
| Queenshill <sup>(3)</sup>                           | 261,750,000   | 14.96%  | 261,750,000  | 14.42%  |
| The Jacobson Pharma (PTC)<br>Limited <sup>(3)</sup> | 39,262,000  | 2.24%   | 39,262,000   | 2.16%   |
| Mrs. Karen Lee                                      | 3,754,000   | 0.22%   | 3,754,000  | 0.21%   |
| New Heritage Healthcare                             | 33,333,000  | 1.90%   | 33,333,000   | 1.84%   |
| Hong Kong Wing Wah                                  | 53,332,000  | 3.05%   | 53,332,000   | 2.94%   |
| Other Public Shareholders                           | 350,835,000   | 20.05%  | 416,460,000  | 22.93%  |
| Total   | <u>1,750,000,000</u>  | <u>100%</u>   | <u>1,815,625,000</u>   | <u>100%</u>   |

Notes:

- (1) The percentage figures have been subject to rounding adjustments.
- (2) Kingshill and Longjin are parties acting in concert pursuant to the Deed of Acting in Concert and hence each of them is deemed to be interested in the Shares held by each other. Kingshill is wholly-owned by Trust Co under The Kingshill Trust, a discretionary trust established by Mr. Sum (as the settlor). Longjin is owned as to 75% by Mr. Lau.
- (3) Queenshill is the settlor of the trust established for the purpose of holding the Shares under the Share Incentive Scheme. The Jacobson Pharma (PTC) Limited is the trustee of such trust. Mr. Sum is the sole shareholder of Queenshill. By virtue of the SFO, Mr. Sum and Queenshill are deemed to be interested in the 39,262,000 Shares held by The Jacobson Pharma (PTC) Limited.

The additional net proceeds of approximately HK\$95.3 million from the issue of the Over-allotment Shares after deducting the commissions, fees and expenses relating to the exercise of the Over-allotment Option will be used by the Company for the purposes as set out in the section headed “Future Plans and Use of Proceeds” in the Prospectus.

## **PUBLIC FLOAT**

Immediately after the issue and allotment of the Over-allotment Shares, the Company will continue to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules that at least 25% of the Company’s total issued share capital must at all times be held by the public. No new Shares or securities convertible into equity securities of the Company may be issued within six months from the Listing Date save for the situations set out in Rule 10.08 of the Listing Rules.

A further announcement will be made by the Company at the end of the stabilisation period in connection with the Global Offering, pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

By order of the Board  
**Jacobson Pharma Corporation Limited**  
**Wong Wai Ming**  
*Company Secretary*

Hong Kong, 3 October 2016

*As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chief Executive Officer), Mr. Lo Chun Bun and Mr. Yim Chun Leung as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Professor Chow Hee Lum, Albert, Dr. Lam Kwing Tong, Alan and Mr. Young Chun Man, Kenneth as independent non-executive Directors.*